← Eichor
Study identifier: NCT02431845 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

Condition: Obsessive-Compulsive Disorder  ·  Sponsor: Severance Hospital

PhaseNA
Planned participants200
Who can joinAll sexes, 19 Years to 70 Years
Healthy volunteersNo

About this study

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

This description comes directly from the study's public registry record.

Talk to the study team

Se Joo Kim, M.D.  ·  +82-2-2228-1627  ·  kimsejoo@yuhs.ac

Jee In Kang, M.D.  ·  +82-2-2228-1630  ·  jeeinkang@yuhs.ac

Always discuss trial participation with your own doctor first.

Locations (1)

Yonsei Univ. Health System Severance HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02431845